The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

In human cells, only a small proportion of the information written in genes is used to produce proteins. How does the cell ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Human genes that encode proteins often contain non-coding segments known as introns. Removing introns is crucial for the proper expression of genetic information. Understanding how our cells ...

Jones Trading initiated coverage on ProQR Therapeutics N.V. (NASDAQ:PRQR) with a Buy rating and set a price target of $11.00, representing significant upside from the current price of $2.19. The ...

JonesResearch analyst Catherine Novack initiated coverage of ProQR Therapeutics (PRQR) with a Buy rating and $11 price target The firm says ...

A new study has uncovered a novel P-type PPR protein, BoYgl-2, which plays a crucial role in chloroplast RNA editing and chlorophyll biosynthesis in cabbage.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand ...

Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...